Per Norlén (CEO)
Per Norlén - born 1970, CEO – is a medical doctor with board certification in clinical pharmacology, and a PhD and associate professorship in clinical pharmacology at Lund University. Per Norlén has 25 years of research experience in pharmacology including 15 years of experience in clinical drug development. Employed since 2015 and member of the Management Team since 2010.
Other current positions: Chairman of A Bioscience Incentive AB. Board member of Atlas Therapeutics AB .
Holdings in Alligator: 118,000 shares, 200,000 warrants, 250,000 employee stock options in program 2016/2020 and 230,000 employee stock options in program 2018/2022.
Anu Balendran (VP BD)
Anu Balendran – born 1975, VP Business Development – holds a PhD in Biochemistry from University of Dundee, UK. Anu has close to 20 years’ experience from different positions within AstraZeneca R&D, the last eight years in international business development, most recently as External Innovation Director. Employed since 2018 and member of the Management Team since 2018.
Other current positions: None
Holdings in Alligator: 4,000 shares and 135,000 employee option stocks in program 2018/2022.
Malin Carlsson (COO)
Malin Carlsson - born 1968, Chief Operating Officer – is a medical doctor with board certification in clinical immunology at Lund University. Malin has 20 years of research experience in immunology 12 years of experience in clinical drug development. Employed since 2020 and member of the Management Team since 2020.
Other current positions: None
Holdings in Alligator: No holdings
Peter Ellmark (VP Discovery)
Peter Ellmark – born 1973, VP Discovery – holds a PhD and an associate professorship in Immunotechnology at Lund University. Peter has more than 15 years’ experience of developing antibodies for immunotherapy of cancer. Employed since 2008 and member of the Management Team since 2018.
Other current positions: None
Holdings in Alligator: 10,000 shares, 50,000 warrants, 50,000 employee stock options in program 2016/2020 and 135,000 employee stock options in program 2018/2022.
Christina Furebring (SVP Preclinical Development)
Christina Furebring – born 1964, SVP Preclinical Development – holds a PhD in immune technology from Lund University. She is also a co-founder of the FIND technology which is a cornerstone of Alligator’s technology platform. Christina has more than 20 years’ experience of working on the optimization of proteins and antibodies. Employed since 2001 and member of the Management Team since 2001.
Other current positions: Deputy Board Member in A Bioscience Incentive AB and Atlas Therapeutics AB.
Holdings in Alligator: 100,000 shares, 120,000 warrants, 150,000 employee stock options in program 2016/2020 and 135,000 employee stock options in program 2018/2022.
Charlotte A. Russell (CMO)
Charlotte A. Russell – born 1964, Chief Medical Officer – is a medical doctor with board certifications in haematology and internal medicine, and has a PhD in medical science from Copenhagen University. Charlotte has more than 25 years of research and clinical experience, including 10 years with clinical drug development in biotech/pharmaceutical companies. Employed since 2018 and member of the Management Team since 2018.
Other current positions: None
Holdings in Alligator: 135,000 employee stock options in program 2018/2022.
Per-Olof Schrewelius (CFO)
Per-Olof Schrewelius – Born 1963, Chief Financial Officer – has an MSc in Business Administration and Economics from Lund University and has over 20 years of experience from different CFO and Finance Manager positions in various industries including medical technology and engineering. Employed since 2016 and member of the Management Team since 2016.
Other current positions: Board member of A Bioscience Incentive AB.
Holdings in Alligator: 50,000 shares, 125,000 warrants and 135,000 employee stock options in program 2018/2022.